Our pipeline consists of two clinical stage compounds, TBR-760 for the treatment of non-functioning pituitary adenoma (NFPA) and TBR-065 for additional rare endocrine diseases. We were launched out of orphan drug accelerator Cydan with financing from leading life science investors.
NFPA is a non-metastatic tumor in the pituitary gland in the brain with life-altering and potentially life-threatening consequences for patients. Currently there are no approved therapies to treat these tumors and patients must undergo transsphenoidal surgery and/or radiation to remove or shrink the tumor.
Tiburio’s TBR-760 is a potential breakthrough in the treatment of non-functioning pituitary adenoma (NFPA). TBR-760, a dopamine-somatostatin chimeric molecule, inhibits NFPA cell proliferation and has the potential to shrink or halt tumor growth. Tiburio expects to move TBR-760 into a Phase 2 clinical trial in patients with NFPA in the second half of 2019.